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Abstract 
We reported a multicentre study of Chinese children with SLE nephritis in Hong Kong. 
Cases were included if they fulfilled the ACR criteria, had significant proteinuria or 
casturia, were Chinese before 19th birthday, and diagnosed between January 1990 to 
December 2003. Investigators in each centre retrieved data on clinical features, biopsy 
reports, treatment and outcome of these patients. There were 128 patients (8 boys, 120 
girls; aged 11.9+2.8 years). About 50% presented with multisystem illness and 40% with 
nephritic/nephrotic symptoms. Six percent had negative anti-dsDNA antibodies. Renal 
biopsy revealed WHO Class II, III, IV and V nephritis in 13 (10%), 22 (17%), 69 (54%), 
and 13 (10%) patients respectively. The clinical severity of nephritis cannot accurately 
predict renal biopsy findings. Follow up ranged from 1 to 16.5 years (mean+SD = 
5.76+3.61 yrs). Overall five patients died (due to lupus flare in two, cardiomyopathy in 
one, infections in two). Four patients had endstage renal failure (one died during a lupus 
flare). All deaths and ESRF occurred in Class IV nephritis group. Chronic organ damages 
were infrequent in survivors. The actuarial patient survival rates at 5-, 10- and 15-years 
were 95.3%, 91.8%, and 91.8% respectively. For Class IV nephritis patients, the survival 
without ESRF at 5-, 10-, and 15-years were 91.5%, 82.3%, and 76% respectively. The 
survival and chronic morbidity of Chinese SLE children were comparable to previous 
published reports. 
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Introduction 
Systemic lupus erythematosus (SLE) is the commonest autoimmune disorder with 
renal involvement that leads to chronic kidney disease. About 10-15% of SLE patients 
had their diagnosis made in childhood.[1] It was reported that childhood-onset SLE 
patients were different from adult patients, in that they have more nephritis, more central 
nervous system involvements,[2] and more thrombotic thrombocytopenic purpura 
(TTP).[3] Moreover, some authors reported a poorer outcome in paediatric SLE 
patients[4] while others did not observe such a difference.[5;6] There were also reported 
ethnic differences in the incidence and severity of SLE patients such that African 
Americans and Hispanic patients were worse than the White patients.[7-9] Most of these 
reports were small case-series and limited by referral bias as they came from tertiary 
paediatric centres. There were only scanty data on SLE nephritis in the Chinese 
population. Most publications were on adult Chinese patients[10-12] and the only report 
on Chinese children was made a decade ago from a referral centre.[13] This study aimed 
at providing updated data on SLE nephritis in Chinese children, by descirbing a territory-
wide cohort of unselected paediatric patients in Hong Kong. In addition to the clinical 
features and treatment, the mortality and long term morbidity of these children were also 
reported. 
 
Patients and Methods 
Hong Kong has a total population of 6.7 million, of which 95% were Chinese, and 
21.7% were aged 18 years or below. Since 1990, the Hospital Authority of Hong Kong 
operated all the public hospitals in Hong Kong and covered 90-94% of patient services in 
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the territory. All eleven paediatric units in the Hospital Authority hospitals participated in 
this retrospective study. Patients diagnosed to have SLE nephritis between 1st January 
1990 to 31st December 2003 were retrieved from hospital/departmental databases and 
crosschecked with renal pathology databases. Patients were included if 1) they were 
Chinese with SLE diagnosed before their 19th birthday; 2) they fulfilled the American 
College of Rheumatology criteria for diagnosis of SLE; 3) they had persistent significant 
proteinuria (urine protein/creatinine ratio of 0.5 mg/mg or more) or had active urine 
sediments with erythrocytes and casts; and 4) they had at least one year of follow up data. 
For the purpose of reviewing a homogeneous Chinese cohort, patients of other ethnicity 
were excluded. 
The record of each patient was reviewed and data were extracted into a standard 
questionnaire. Data collected included age at first presentation, at diagnosis, and onset of 
nephritis; the clinical features and worst laboratory results within 3 months of diagnosis; 
the renal biopsy reports; induction and maintenance treatment and their response; the 
clinical and renal status at one year after nephritis, their complications, and outcome at 
last follow up. 
Haematuria was defined as positive haemastix or 10 erythrocytes per high power 
field on urine microscopy on 3 occasions. Proteinuria was defined as urine protein to 
creatinine ratio in mg/mg (Up/c) of 0.2 or more on 3 occasions. Glomerular filtration rate 
(eGFR) was estimated by Schwartz formula from body height and serum creatinine. 
Nephrotic syndrome was defined as the presence of oedema, massive proteinuria (Up/c > 
2) and hypoalbuminaemia (serum albumin < 25 g/L). Nephritic syndrome was defined by 
haematuria, hypertension and renal impairment with eGFR <90 ml/min/1.73m2.  
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Hypertension was defined as persistent elevation of blood pressure above 95th percentile 
for age and gender, and those requiring anti-hypertensive treatment. Antinuclear antibody 
(ANA) was measured by indirect immunofluorescence and a titre of 1/80 or higher was 
reported as positive. Anti-double strand DNA antibodies (anti-dsDNA) was measured by 
enzyme-linked immunosorbent assay (ELISA) using commercial kits and reported 
positive when it was above the quoted reference ranges. All samples for anti-Ro, La, and 
Sm antibodies were measured by counter-current immunoelectrophoresis in a single 
university laboratory with in-house reference sera characterised by comparison with CDC 
reference sera for the respective antibody. Anti-cardiolipin IgG and IgM were studied by 
ELISA with upper limits of normal as 15 GPL/ml for IgG and 13 MPL/ml for IgM. 
All renal biopsy specimens were examined by light microscopy with standard 
staining, immunofluorescence, and electron microscopy. They were interpreted by renal 
pathologists in individual hospitals and were classified according to the World Health 
Organization (WHO)[14]: Class II being mesangial glomerulonephritis; Class III being 
focal proliferative glomerulonephritis; Class IV being diffuse proliferative 
glomerulonephritis; Class V being membranous nephropathy. For the purpose of analysis 
of presenting features and outcome, mixed Class III+V and Class IV+V nephritis were 
grouped as Class III and Class IV respectively, while Class II+V nephritis was grouped 
with pure Class V nephritis. 
Patients were categorized according to the induction therapy they had received for 
their nephritis: In Group 1, high-dose prednisolone at 2 mg/kg/day was given till 
remission. In Group 2, patients received high-dose prednisolone plus azathioprine (AZA) 
at 1-3 mg/kg/day as tolerated. Group 3 patient were treated with high-dose prednisolone 
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plus oral cyclophosphamide (POCYC) at 2 mg/kg/day for 3-6 months. Group 4 patients 
received high-dose prednisolone plus monthly intravenous cyclophosphamide (IVCYC) 
pulses at 500-1000 mg/m2 for 6 months. In Group 5, high-dose prednisolone plus 
mycophenolate mofetil (MMF) at 750-1200 mg/m2/day were given. Group 6 patients 
received high-dose prednisolone plus cyclosporine A (CSA) at 3-5 mg/kg/day. In all 
groups, oral prednisolone doses were tailed down gradually as maintenance therapy. 
Group 3 patients were switched to azathioprine, while Group 4 patients received either 
quarterly IVCYC for 2 years or MMF or AZA as maintenance. Patients in other groups 
also received the same induction cytotoxic agent for maintenance.  
The renal status at one year after onset of nephritis was described as: complete 
remission CR (having no clinical symptoms of activity, Up/c <0.2, normal serum albumin 
and eGFR); partial remission PR (remission of clinical symptoms, >50% improvement in 
Up/c or eGFR); and non-response NR (no change in clinical status and <50% 
improvement in Up/c or eGFR). Relapses were defined as recurrences of clinical disease 
and worsening of C3/C4 and serology and requiring clinicians to increase therapy to high 
dose prednisolone (1mg/kg/day) or adding another immunosuppressive drugs for control. 
Additional drugs used for relapsers were recorded. 
The clinical activity at diagnosis and one year after nephritis were assessed by 
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).[15] The SLEDAI is a 
weighted, cumulative index and has 24 attributes grouped into 9 organ systems. Each 
attribute when present within 10 days before the assessment time was given a certain 
score. The overall index is the sum of all scores and may range from 0 to 105, with 0 
being no disease activity. The chronic morbidity at one year and at last follow up was 
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assessed using the Systemic Lupus International Collaborating Clinics/American College 
of Rheumatology Damage Index (SDI).[16] The SDI consists of 41 items in 12 different 
domains, and it measures irreversible damage because each item is given a score when 
present for at least 6 months continuously. The total SDI score can range from 0 to 47 
with 0 being no chronic damage. The SDI has recently been applied to childhood-onset 
SLE patients and found to have face, content and construct validity.[17] The project was 
approved by various Cluster Ethics and Research Committees of Hospital Authority. 
Statistical analysis 
The incidence of lupus nephritis was estimated by dividing the number of new 
cases by the estimated childhood population aged 0-18 years (as person-years of the at-
risk population, obtained from Census and Statistics Department of Hong Kong 
Government) over the period of interest. The average incidences of lupus nephritis were 
calculated for each 3-year period from 1992-1994, 1995-1997, 1998-2000, 2001-2003 to 
show the changing trend of incidence over the past decade.   
Summary statistics of all data were presented as mean+SD or range or frequency 
distribution. Survival data were presented as Kaplan-Meier survival curves. Differences 
between subgroups were tested for statistical significance by log-rank tests. Multiple 
logistic analysis of the risk factors for death/ESRF was performed using the Cox 
proportional hazard model. SPSS version 10.0 was used for statistical analysis. 
Results 
Our search identified 128 children with SLE nephritis within this 14-year period. 
They were all Chinese children. There were 120 girls and 8 boys with age at diagnosis 
ranging from 3.6 to 18.6 years (mean+SD 11.9+2.8 years). The age and sex distributions 
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are shown in Table 1. For each 3-year period of 1992-1994, 1995-1997, 1998-2000, and 
2001-2003, there were 21, 22, 33 and 40 new cases of lupus nephritis respectively, while 
the total person-years of risk were 4 506 455, 4 629 956, 4 553 407, and 4 315 426 
respectively. Thus the incidence of lupus nephritis were estimated to be 0.47, 0.48, 0.72, 
and 0.93 per 100 000 person-years for the above time periods. During the study period 
from 1990 to 2003, 1157 renal biopsies were performed in children aged 18 years or 
below. 
Their presentations mainly fell into two patterns. Sixty-five patients (50.8%) had  
multisystemic symptoms of prolonged fever, polyarthritis and skin rash while renal 
involvements were indicated by urinary abnormalities only. In 51 patients (40%), the 
presence of nephrotic or nephritic features brought them to medical attention before the 
diagnosis of SLE. Other rare presenting features were immune thrombocytopenic purpura 
(2 patients), autoimmune haemolytic anemia (2 patients), pANCA-positive crescentic 
glomerulonephritis (1 patient), deep vein thrombosis (2 patient), renal arterial and venous 
thrombosis (1 patient), Raynaud’s phenomenon (1 patient), intestinal vasculitis with 
intestinal bleeding, abdominal pain and ascites (1 patient). The patient with pANCA 
crescentic glomerulonephritis first presented at the age of 11 years with proteinuria, 
microhaematuria and renal impairment. She was positive for antinuclear antibody but 
negative for anti-dsDNA. She had strongly positive ANCA (perinuclear pattern) and anti-
myeloperoxidase titre. Renal biopsy revealed fibrocellular crescents in all 6 glomeruli 
seen, with immunofluorescent staining showing weak IgG, C3 and C1a staining and 
negative IgA and IgM staining. She was treated with pulse methylprednisolone followed 
by oral prednisolone and cyclophopshamide/azathioprine maintenance for 3 years. There 
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was initial response but she relapsed at age of 15 years with full blown nephrotic 
syndrome, Coomb’s positive haemolytic anaemia, and positive ANF and anti-dsDNA. 
Repeated renal biopsy showed diffuse proliferative glomerulonephritis with full house 
immunofluorescence staining.  
Diagnosis of SLE was made usually within 3 months of onset of symptoms, but 
there was a delay of 3 to 12 months in 9 patients and of more than 1 year in 13 patients 
especially in those with the rare presenting features. Evidence of renal involvement was 
present at diagnosis in 92 patients, and developed within the first year of diagnosis in  an  
additional 19 patients.  However, in 17 patients, nephritis occurred more than one year 
after diagnosis of SLE. 
Table 1 and 2 show the prevalence of various clinical features and significant 
laboratory tests within 3 months of SLE diagnosis in this cohort. Of special interest were 
8 patients (6%) who had no detectable anti-dsDNA antibodies (sero-negative lupus). 
While anti-cardiolipin antibodies were prevalent (50.6% for IgG and 38.8% for IgM), 
lupus anti-coagulants were rare (positive in 17.4%), and clinical thrombosis occurred in 
only 4 patients. Three of these patients had typical SLE features including malar rash, 
leucopenia and thrombocytopenia, haematuria and proteinuria, positive ANF and anti-
dsDNA and they developed deep vein thrombosis over the lower limbs 8 months before 
(1), at diagnosis (1) and 5 years after SLE diagnosis (1). They all had positive 
anticardiolipin and lupus anticoagulatnt antibodies. The fourth patient presented with 
polyarthritis, pleural effusion, Coomb’s positive haemolytic anaemia, thrombocytopenia 
and gross haematuria. Ultrasound scan and Doppler revealed right kidney enlargement 
and artery and vein thrombosis. Her renal biopsy also yielded necrotic renal tissue 
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suggestive of infarction. She also had positive anti-dsDNA and lupus anticoagulant 
antibodies.  
TTP was evident at SLE diagnosis in 4 patients. All of them had systemic SLE 
features, blood and renal involvement and positive ANF and anti-dsDNA antibodies. TTP 
was diagnosed in these patients because of the features of micro-angiopathic haemolytic 
anaemia on peripheral smear examination, thrombocytopenia and renal impairment. The 
renal biopsy also showed fibrin thrombi in some arterioles in addition to diffuse 
proliferative glomerulonephritis and full house immunoflurescence staining.  
Table 4 shows that Class IV nephritis was the most common renal pathology, 
followed by Class III, V and II. There was a general trend that Class IV and V nephritis 
were associated with more severe renal manifestations with nephrotic syndrome or renal 
impairment. However, a significant proportion of patients with urinary abnormalities 
(38.9%) or those with normal eGFR and non-nephrotic-range proteinuria (28.6%) also 
had Class IV nephritis on initial biopsy. If patients with these renal manifestations were 
not subjected to renal biopsy, 15-30% of Class IV nephritis would have been missed.  
Table 5 shows the variety of induction treatment that patients with different renal 
pathologies had received, and Table 6 shows their renal status at one year, relapses, need 
for additional treatment, and outcome at last follow up. All of the cases ending in death or 
end-stage renal failure (ESRF) occurred in Class IV patients.  In the Class IV patients, 
those treated with prednisolone alone or prednisolone plus POCYC had a greater need for 
additional therapies and more severe renal sequalae (ESRF or impaired eGFR) while 
patients treated with IVCYC had good control of nephritis but more deaths which were 
related to treatment.  
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The duration of follow up ranged from 1 to 16.5 years with a median of 5.3 years 
(mean + SD 5.76+3.61 years). Twenty-four patients were followed up for 10 or more 
years. Five (3.9%) patients died. One patient with Class IV nephritis was treated with 
prednisolone alone in the earlier years. She had poorly controlled nephritis despite 
subsequent addition of POCYC. She died with multiorgan failure in a lupus flare 2.6 
years after diagnosis. One patient had Class IV nephritis which was well controlled after 
IVCYC but at 3.1 years from diagnosis he died suddenly due to myocarditis and cardiac 
tamponade during an acute flare. There were two deaths from infection. Both had Class 
IV nephritis treated with IVCYC regime. One died of tuberculous meningoencephalitis at 
5.3 years and the second died of septicaemic shock at 9.8 years after diagnosis. Both had 
massive proteinuria though normal eGFR at the time of death. The fifth patient initially 
had Class V nephritis but subsequently developed crescentic Class IV nephritis despite 
POCYC induction.  She had renal failure with eGFR 15 ml/min/1.73 m2 at 5.5 years after 
diagnosis, when she opted for haematopoietic stem cell transplantation. However she 
died of cyclophosphamide-related cardiomyopathy during the conditioning phase.  
Overall the patient survival rates at 5-years, 10-years and 15-years from diagnosis 
of SLE were 95.3%, 91.8% and 91.8% respectively. The 5-years, 10-years and 15-years 
renal survival rates (survival without ESRF) were 94.1%, 87.4% and 81.7% respectively. 
For Class IV nephritis patients, the 5-years, 10-years and 15-years renal survival rates 
were 91.5%, 82.3% and 76% respectively. There were no statistical differences in renal 
survival rates between different WHO classes of the initial biopsy (Figure). Analysis with 
the Cox proportional hazard model was performed with the outcome of death/ESRF and 
prognostic variables including sex, age at nephritis, persistent hypertension, Up/c and 
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eGFR at presentation, presence of Class IV nephritis, presence of membranous 
components in biopsy, induction therapy, Up/c, eGFR and SLEDAI at 1 year. It showed 
that only Up/c at presentation (B=0.615, SE= 0.28, p=0.028) and SLEDAI at 1 year 
(B=0.005, SE=0.002, p=0.03) were significant prognostic factors for death/ESRF.  
Of the 123 survivors, 79 patients (64.2%) had no chronic organ damage at their 
last follow up. Twenty-seven patients (22%), eight patients (6.5%) and nine patients 
(7.3%) had a SDI of one, two and more than two respectively. Table 7 showed the organ-
system distribution of SDI scores. The commonest organ damages occurred in renal,  
musculoskeletal systems and the eyes. ESRF occurred in 3 survivors (in addition, one 
death case also had ESRF). Two patients had renal impairment with eGFR<50 
ml/min/1.73m2, and 16 had nephrotic-range proteinuria. Nine patients (7.3%) developed 
avascular necrosis (8 had AVN of both femoral heads and one had AVN of talus). 
Cataracts were detected in 17 patients though all were partial (13.8%). Significant 
neurological sequalae and osteoporosis with fractures each occurred in only 1-2% of the 
survivors. Table 8 showed the infectious complications reported in our patients. Although 
infections were infrequent with only 53 episodes reported in 810 patient-years of follow-
up (giving an incidence of 0.65 episodes per 10 patient-years), some infections were life-
threatening and accounted for two deaths in our cohort. 
Discussion 
 This study provided us with useful information on the epidemiology, clinical 
features, clinicopathologic correlation, treatment and outcome of an unselected cohort of 
SLE nephritis in Chinese children. We believe that this is representative of the local 
Chinese population because it involved a good sized sample of 128 children collected 
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over a 14-year period. The participating units included all hospitals that together provided 
more that 90% of both secondary and tertiary care to children in Hong Kong, thus 
avoiding selection bias commonly encountered in previous reports from tertiary centres.  
In this Chinese cohort lupus nephritis occurred before 10 years old in 23% (rare 
before 5 years), and between 10 and 15 years in 70%. This was in agreement with the 
data of 556 children in the Pediatric Rheumatology International Trial Organization 
(PRINTO) which showed that 23% of childhood SLE had onset before 10 years.[3] Our 
cohort had a female to male ratio (F:M) of 2:1 before 5 years and 7.7:1 from 5 to 10 years. 
This was similar to previous reports by Cassidy et al (F:M of 4:3), King et al[18] (F:M 
3:1) and the recent PRINTO data (F:M 5.3:1).[3] However, for patients above 10 years 
old, the F:M ratio of 20.8:1 in our cohort was much higher than the figures of 5:1 
reported by Cassidy et al, or 5.8:1 by the PRINTO dataset[3]  or 10:1 reported by King et 
al,[18]. This indicated the extreme rarity of male SLE in Chinese teenagers. 
The overall incidence of SLE in all age-groups ranged from 1.9 to 8.7 per 100 000 
population.[19] In the review by Cassidy and Ross, the incidence of SLE in children 
younger than 15 years were estimated to be 0.36 to 0.9 per 100,000 based on studies in 
1970’s.[20] We found an incidence of SLE nephritis in Chinese children ranging from 
0.47 to 0.93 per 100 000 person-years. However these figures are not directly comparable 
as SLE nephritis is only a subset of all SLE patients. Another interesting finding in the 
present study was that the incidence had doubled from 1992 to 2003. This could be due to 
better recognition and documentation of renal involvement in SLE children, or it could be 
a genuine increase in the incidence of SLE nephritis in the Chinese population. 
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Roughly the same proportions presented with either the typical multi-system 
features of SLE (with nephritis indicated by urinary abnormalities only), or full blown 
nephrotic or nephritic features. Correlation with biopsy findings reiterated the general 
concept that the clinical presentations could not always predict WHO histopathologic 
classes. Hence renal biopsy should form part of the assessment in deciding on therapy for 
patients with any renal involvement. If renal biopsy was not performed in the patients 
with only urinary abnormalities or in those with normal eGFR and non-nephrotic 
proteinuria, a significant proportion of Class IV nephritis may have been missed. 
Although prior immunosuppressive treatment might have modified the clinical 
manifestations, it was not likely in our patients because most of them underwent renal 
biopsy at diagnosis of SLE before start of any therapy. 
Since this was a territory-wide cohort, our review gave a fair estimate of the 
prevalence of seronegative lupus (6%), concurrent TTP (3%), and antiphospholipid 
syndrome (3%) in childhood lupus nephritis. TTP is a recognised association of SLE. 
Brunner reviewed 35 patients with childhood-onset TTP and found that 17 (49%) 
subsequently received the diagnoses of definite or incipient SLE.[21] However, TTP was 
not included as a complication or association in several large series of childhood 
SLE.[5;13;22] The prevalence of anticardiolipin antibodies in adult patients with SLE 
ranged from 12-30%, and those of lupus anticoagulants were 15-34%. After 20 years of 
follow up, 50-70% of these patients developed into antiphospholipid syndrome.[23] Our 
data indicated a higher prevalence (30-50%) of anticardiolipin antibodies, but a lower 
percentage (3% of the cohort or 10% of those with positive anticardiolipin antibodies) 
developed into antiphospholipid syndrome with genuine thromboembolism. However this 
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may be an underestimate since more patients may develop thrombosis on further follow 
up. 
The treatment recommendations for adult SLE nephritis were well founded on 
good quality randomized controlled trials.[24] In children, data from randomized clinical 
trials were nonexistent and treatment recommendations were extrapolated from adult 
studies or derived from past reports of case series. Though most investigators suggested 
steroid plus POCYC or IVCYC as the standard therapy for Class IV nephritis, some 
authors have reported good results with steroid plus AZA, and they could not 
demonstrate any difference between AZA and CYC therapy.[25-27] Although our data 
were retrospective and non-randomized, we observed that all patients who died or 
developed ESRF (except one death) had Class IV nephritis at onset of disease. Those 
patients who received steroid alone had the worst outcome. While patients treated with 
POCYC developed ESRF, those treated with IVCYC died of complications of therapy 
(infections and cyclophosphamide cardiomyopathy). This was not observed in a report of 
adult Chinese SLE patients in which POCYC was found to be more effective but more 
toxic than IVCYC regimes.[28] Multivariate analysis, however, did not show any 
statistically significant differences in renal survival between different biopsy classes or 
different therapy, probably because of the small number of death/ESRF involved. 
 The prognosis of SLE nephritis in children has improved over the past 3 decades. 
Meislin et al in 1968 reported a 5-year patient and renal (alive without ESRF) survival 
rate of 43%.[4] In the 1990’s, the 5-year patient and renal survival reported for SLE 
nephritis were 78% and 56% by McCurdy et al,[29] or 82.8% and 44.4% by Baqi et 
al.[26] Recent publication by Hagelberg in 2002 reported 5-, 10- and 15-year patient 
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survival rates to be 97%, 95% and 90% respectively.[25] In our study, the  patient 
survival rates were 95.3% at 5 years and 91.8% at 10 years, while the renal survival rates 
94.1% at 5-year and 87.4% at 10-years respectively. These figures were comparable to 
those reported by Hagelberg et al[25], Emre et al,[30], and Bogdanovic et al.[31]  
 Our series also had similar 5-year patient and renal survival rates when compared 
to the report by Yang et al from Taiwan in 1994 (95.3% and 91.8% in our series versus 
93.1% and 91.1% reported by Yang respectively).[13] However our Class IV nephritis 
patients had better survival than their patients (91.5% versus 82% at 5-years). We also 
had longer follow-up data at 10 and 15 years. Understandably there was a gap of 10 years 
between the two reports, and our series included unselected patients of all severity while 
their patients were from a tertiary referral centre. When compared with adult Chinese 
patients, our series had slightly better outcome. Mok et al in 1999 analysed the outcome 
of adult Chinese SLE nephritis patients from the same community as ours. They reported 
patient survival rates of 98.8%, 94.4% and 94.4% at 5-, 10- and 15-years respectively, 
while the renal survival rates were 92.1%, 81.2% and 75.2% at 5-, 10-, and 15-years 
respectively.  For Class IV nephritis adults, the renal survival rates were 89.1%, 71.1% 
and 61.4% at 5-, 10- and 15-years respectively.[10]  
 Data on chronic morbidity of SLE nephritis children were scarce in the literature, 
especially using standardized scoring systems such as the SDI. Our study showed that at 
the last follow up, 13.8% of survivors had two or more SDI. This percentage was much 
lower than the incidence of 51% of patients having an SDI of >2 in the report by 
Miettunen et al.[32] Compared with their series, our patients also had less chronic 
morbidity in the neuropsychiatric, cardiovascular or peripheral vascular systems.  
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 In summary we described a representative cohort of Chinese children with SLE 
nephritis in Hong Kong. When compared with previous reports, SLE nephritis was rare in 
Chinese boys especially in teenage years. About half presented as multisystem disease 
and half presented with predominantly renal manifestations. On initial renal biopsy, 70% 
of patients had Class III and IV nephritis. Our experience supported the practice to 
perform renal biopsy on all SLE patients with evidence of nephritis. Though it was 
believed that non-Caucasian patients had worse prognosis, our series of Chinese children 
had good medium term survival similar to previous reports in the Caucasian population. 
Nevertheless death occurred due to lupus flare or infections, which reflected a delicate 
balance between adequate immunosuppression and overtreatment. Lastly we described 
chronic organ damage in our patients (as the standardized SDI), which was less common 
in our series than other reports. However renal damage and avascular necrosis of both 
hips were common long-term complications in our patients. 
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Table 1. Age and sex distribution of 128 children with lupus nephritis 
 
Age group Female Male Total Female: male ratio 
0-4.99 years 2 1 3 (  2.3%) 2.0 :1 
5-9.99 years 23 3 26 (20.3%) 7.7 : 1 
10-14.99 years 83 4 87 (70.0%) 20.8 :1 
15-18.99 years 12 0 12 (  9.4%) NA 
NA not assessable
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Table 2: Clinical features in 128 Chinese children with SLE nephritis at the time of initial 
diagnosis. 
 
Clinical features at diagnosis No. present  
/ No. recorded 
Prevalence 
(%) 
Systemic symptoms 
  
Prolonged fever 
71/128 55.5 
Malar rash 59/126 46.8 
Polyarthritis 
57/128 44.5 
Skin vasculitis 35/122 28.7 
Lymphadenopathy 22/123 17.9 
Oral ulcers 22/125 17.6 
Pericardial effusions 21/125 16.8 
Photosensitivity 18/123 14.6 
Alopecia 15/124 12.1 
Discoid lupus 12/124 9.7 
Seizures 12/127 9.4 
Pleural effusion 11/126 8.7 
Livedo reticularis 6/118 5.1 
Raynaud's phenomenon 4/121 3.3 
Skin ulcers 4/122 3.3 
Psychosis 3/127 2.4 
Phlebitis 1/122 0.8 
Renal symptoms:   
Haematuria microscopic 101/126 80.2 
Oedema 69/128 53.9 
Hypertension 41/128 32.0 
Urine casts 22/70 31.4 
Haematuria gross 13/126 10.3 
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Table 3: Selected laboratory findings in 128 Chinese children with SLE nephritis at the 
time of initial diagnosis. 
 
Laboratory features at diagnosis No. present  
/ no. tested 
Prevalence 
(%)  
Haematology tests   
Direct Coomb's test positive 74/124 59.7 
Hb <10 g/dL 
75/128 58.6 
Lymphocytes <1.2 x 109/L 56/126 44.4 
Leukocytes <4.0 x 109/L 52/127 40.9 
Platelet count <100 x 109/L 42/126 33.3 
Serological tests   
ANA positive 128/128 100 
Anti-dsDNA positive 
120/128 93.8 
C3 complement < 0.75 g/L 119/128 93 
C4 complement < 0.14 g/L 103/117 88 
Anti-cardiolipin antibody (IgG) 
positive (>15 GPLU/mL) 
42/83 50.6 
Anti-ro antibody positive 41/88 46.6 
Anti-cardiolipin antibody (IgM) 
positive (>13 MPLU/mL) 
26/67 38.8 
Lupus anticoagulant positive 8/46 17.4 
Anti-la antibody positive 7/86 8.1 
Anti-sm antibody positive 7/88 8 
 
 
Abbreviations: Hb Haemoglobin level; ANA Antinuclear antibodies; Anti-dsDNA 
Antibody to double strand DNA
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Table 4: Correlation of renal histopathology with clinical and laboratory features in 128 Chinese children with SLE nephritis 
 
  Presenting clinical syndromes Normal eGFR eGFR < 90 eGFR <30 
WHO 
Class 
No. in each 
category 
Urinary 
abnormalities
Nephrotic 
syndrome 
Nephritic 
syndrome 
Up/c < 2.0 Up/c >2.0 Up/c < 2.0 Up/c >2.0  
II 13 (10.2%) 11 (20.4%) 2 (4%)  9 (25.7%) 4 (6.5%)    
III 22 (17.2%) 14 (25.9) 4 (8%) 4 (16.7%) 8 (22.9%) 10 (16.1%) 2 (25%) 2 (10%)  
IV 69 (53.9%) 21 (38.9%) 30 (60%) 18 (75%) 10 (28.6%) 34 (54.8%) 6 (75%) 16 (80%) 3 (100%)
V 13 (10.2%) 1 (1.9%) 11 (22%) 1 (4.2%) 1 (2.9%)  11 (17.7%)  1 (5%)  
no/ in-
adequate 
biopsy 
11(8.6%) 7 (13.0%) 3 (6%) 1 (4.2%) 7 (20.0%) 3 (4.8%)  1 (5%)  
Total 128 (100%) 54 (100%) 50 (100%) 24 (100%) 35 (100%) 62 (100%) 8 (100%) 20 (100%) 3 (100%)
 
 
Abbreviations: Up/c urine protein to creatinine ratio in mg/mg; eGFR glomerular filtration rate in ml/min/1.73m2 as estimated by 
Schwartz formula
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Table 5: Initial induction treatment given to 128 Chinese children with SLE nephritis 
 
WHO Class  Induction treatment given  
 No. in 
each 
category 
Group 1 : 
Pred only
Group 2 : 
Pred+ 
AZA 
Group 3: 
Pred+ 
POCYC
Group 4 : 
Pred+ 
IVCYC
Group 5 : 
Pred+ 
MMF 
Group 6 : 
Pred+ 
CSA 
II 
13 9 1 3    
III 22 4 6 7 5a   
IV 69 14 6 25b 21 2c 1 
V 13 3 1 4d 1 2 2 
no/in-
adequate 
biopsy 
11 5 4e 1  1  
Total 128 35 18 40 27 5 3 
 
Notes:  
aone patient also received plasmapheresis for TTP 
bone patient also received plasmapheresis, IVIg, IVCYC for one dose for TTP 
cone patient also received plasmapheresis, IVMP, IVCYC for one dose for TTP, then 
switched to MMF 
done patient also received CSA 
eone patient also received IVIg for renal vein thrombosis 
Abbreviations: AZA azathiorpine; CSA cyclosporine A; IVCYC intravenous 
cyclophosphamide; IVIg intravenous immunoglobulin; IVMP intravenous 
methylprednisolone; MMF mycophenolate mofetil; POCYC oral cyclophosphamide; 
TTP thrombotic thrombocytopenic purpura.  
 
 
 25
Table 6: Treatment responses and outcome in patients with different WHO nephritis 
classes 
WHO Class Class II
(n=13)
Class III
(n=22) 
Class IV
(n=69) 
Class V
(n=13) 
no biopsy 
(n=11) 
Total 
(n=128) 
Complete remission at 1 year 8 13 48 6 8 83 (65%) 
Partial remission at 1 year 4 9 19 6 2 40 (31%) 
Non-response at 1 year 1 0 2 1 1 5 (4%) 
Relapsers 7 8 29 4 4 52 (41%) 
Need for higher level of therapy 9 5 22 4 6 46 (36%) 
Up/c >0.2 but <2.0 at last 
follow up 
3 3 13 3 1 23 (18%) 
Up/c >2.0 at last follow up 2 4 6 2 2 16 (13%) 
eGFR<90 at last follow up 1 0 8 1 1 11 (9%) 
ESRF at last follow up or death 0 0 4* 0 0 4* (3%) 
Death 0 0 4* 1** 0 5* (4%) 
 
Note: *one death case also had ESRF; hence total number of bad outcome was 7 in Class 
IV nephritis and 8 in whole group.  **This patient had transformed to Class IV nephritis, 
needed also plasmapheresis and haematopoietic stem cell transplant but died. 
Abbreviations: Up/c urine protein to creatinine ratio in mg/mg; eGFR estimated glomerular 
filtration rate by Schwartz formula; ESRF endstage renal failure. 
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Table 7: Organ system distribution of SDI scores assessed at last follow-up in 44 patients 
with chronic organ damage. 
 
  
Scores in this organ 
system percentage 
Eye   
       Cataract 12 15.4% 
       Optic atrophy 1 1.3% 
Neurological   
     Cognitive 3 3.8% 
     Cerebrovascular accidents 3 3.8% 
     Neuropathy 2 2.6% 
     Epilepsy 2 2.6% 
Renal     
     Up/c>2.0mg/mg 16 20.5% 
      eGFR<50% 2 2.6% 
     ESRF 9* 11.5% 
Pulmonary   
    Pulmonary fibrosis 1 1.3% 
Cardiac 0 0.0% 
Vascular   
     Venous thrombosis 2 2.6% 
     Minor tissue loss of pulp space 1 1.3% 
Gastrointestinal tract 0 0.0% 
Musculoskeletal   
     Osteoporosis with fracture 3 3.8% 
      Avascular necrosis (AVN) 17** 21.8% 
     Osteomyelitis 1 1.3% 
Skin 2 2.6% 
Gonad 1 1.3% 
Diabetes 0 0.0% 
Cancer 0 0.0% 
Total scores 78 100.0% 
 
Abbrev.: Up/c urine protein to creatinine ratio in mg/mg; eGFR GFR estimated by 
Schwartz formula; ESRF endstage renal failure. 
Note: *3 patients with ESRF with SDI of 3 each. **8 patients had bilateral AVN of 
femoral heads with SDI of 2 each. 
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Table 8: Infectious complications in 128 Chinese children with SLE nephritis 
 
Infectious complications Patient-episodes 
herpes zoster 26 
Cellulitis 4 
Septicemia (Escherichia coli, Pseudomonas, 
Morganella & E.coli) 
3 
Pneumocystis carinii pneumonia 3 
Cytomegalovirus pneumonitis 3 
herpes simplex gingivitis 2 
urinary tract infections 2 
Pneumonia (presumed bacterial) 2 
Septicaemic shock (organism unknown) 1* 
Tuberculous meningoencephalitis 1* 
osteomyelitis (Salmonella sp.) 1 
acute otitis media 1 
breast abscess 1 
candida endophthalmitis 1 
viral meningoencephalitis 1 
viral hepatitis 1 
Total episodes 53 
 
 Note: *resulting in death of patient 
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Legend for figure: 
Kaplan-Meier survival curves for renal survival of patients in each WHO Class 
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